Spexis Valuation

Is SPEX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SPEX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SPEX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SPEX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SPEX?

Key metric: As SPEX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SPEX. This is calculated by dividing SPEX's market cap by their current revenue.
What is SPEX's PS Ratio?
PS Ratio	5.7x
Sales	CHF 595.35k
Market Cap	CHF 3.38m

SPEX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	18.9x
Enterprise Value/EBITDA	-0.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does SPEX's PS Ratio compare to its peers?

The above table shows the PS ratio for SPEX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	4.4x
OBSN ObsEva	0.008x	n/a	CHF 140.6k
ADXN Addex Therapeutics	9.4x	44.2%	CHF 5.6m
RLF Relief Therapeutics Holding	7.3x	n/a	CHF 62.7m
SANN Santhera Pharmaceuticals Holding	0.9x	26.8%	CHF 96.8m
SPEX Spexis	5.7x	n/a	CHF 3.4m

Price-To-Sales vs Peers: SPEX is expensive based on its Price-To-Sales Ratio (5.7x) compared to the peer average (4.4x).

Price to Sales Ratio vs Industry

How does SPEX's PS Ratio compare vs other companies in the European Biotechs Industry?

38 Companies	Price / Sales	Estimated Growth	Market Cap

38 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: SPEX is good value based on its Price-To-Sales Ratio (5.7x) compared to the European Biotechs industry average (7.9x).

Price to Sales Ratio vs Fair Ratio

What is SPEX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SPEX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	5.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SPEX's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Gerresheimer

€2.6b

Manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally.

GXI

€75.60

Roche Holding

CHF 204.3b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.

ROG

CHF 254.30

-0.6%

6.5%

Cosmo Pharmaceuticals

CHF 1.0b

Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.

COPN

CHF 62.80

-1.3%

58.4%